

PRASTERONE pessaries (Intrarosa® ▼) for vulvar and vaginal atrophy

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of PRASTERONE pessaries (Intrarosa® ▼) for the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms.

GREY

Prasterone (Intrarosa® ▼) is indicated for the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms.¹

An in-year application has been received and this recommendation has been prioritised for review by the New Medicines Subgroup.

In the meantime, prescribers should continue to follow national guidance and local formulary choices for the treatment of vulvar and vaginal atrophy in postmenopausal women.

- > NICE Guideline NG23 (November 2015): [Menopause: diagnosis and management](#)
- > Clinical Knowledge Summaries (March 2017): [Menopause](#)
- > Pan Mersey APC Formulary: [Treatment of vaginal and vulval conditions](#)

References

1. Theramex UK Limited. Summary of Product Characteristics. [Intrarosa 6.5 mg pessary](#), September 2018. Accessed online 15 April 2019

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.